Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 130 entries
Sorted by: Best Match Show Resources per page
[An interview with Dr. D. Poggiolini, director of the Pharmaceutical Service of the Health Ministry and the Drug Committee of the EEC. Interview by Giuseppe Lojacono].

Epidemiologia e prevenzione

Poggiolini D.
PMID: 2978859
Epidemiol Prev. 1988 Dec;10(37):9.

No abstract available.

Cite
Poggiolini D. Intervista al dott. D. Poggiolini, direttore del servizio Farmaceutico del Ministero della Sanità e del Comitato dei Farmaci della CEE. [An interview with Dr. D. Poggiolini, director of the Pharmaceutical Service of the Health Ministry and the Drug Committee of the EEC. Interview by Giuseppe Lojacono]. Epidemiol Prev. 1988;10(37):9
Poggiolini, D. (1988). Intervista al dott. D. Poggiolini, direttore del servizio Farmaceutico del Ministero della Sanità e del Comitato dei Farmaci della CEE. [An interview with Dr. D. Poggiolini, director of the Pharmaceutical Service of the Health Ministry and the Drug Committee of the EEC. Interview by Giuseppe Lojacono]. Epidemiologia e prevenzione, 10(37), 9.
Poggiolini, D. "Intervista al dott. D. Poggiolini, direttore del servizio Farmaceutico del Ministero della Sanità e del Comitato dei Farmaci della CEE." [An interview with Dr. D. Poggiolini, director of the Pharmaceutical Service of the Health Ministry and the Drug Committee of the EEC. Interview by Giuseppe Lojacono]. Epidemiologia e prevenzione vol. 10,37 (1988): 9.
Poggiolini D. Intervista al dott. D. Poggiolini, direttore del servizio Farmaceutico del Ministero della Sanità e del Comitato dei Farmaci della CEE. [An interview with Dr. D. Poggiolini, director of the Pharmaceutical Service of the Health Ministry and the Drug Committee of the EEC. Interview by Giuseppe Lojacono]. Epidemiol Prev. 1988 Dec;10(37):9. Italian. PMID: 2978859.
Copy Download .nbib Format: NLM
Cost-effectiveness of nanomedicine: the path to a future successful and dominant market?.

Nanomedicine (London, England)

Bosetti R.
PMID: 26139120
Nanomedicine (Lond). 2015 Jul;10(12):1851-3. doi: 10.2217/nnm.15.74.

No abstract available.

Cite
Bosetti R. Cost-effectiveness of nanomedicine: the path to a future successful and dominant market?. Nanomedicine (Lond). 2015;10(12):1851-3doi: 10.2217/nnm.15.74.
Bosetti, R. (2015). Cost-effectiveness of nanomedicine: the path to a future successful and dominant market?. Nanomedicine (London, England), 10(12), 1851-3. https://doi.org/10.2217/nnm.15.74
Bosetti, Rita. "Cost-effectiveness of nanomedicine: the path to a future successful and dominant market?." Nanomedicine (London, England) vol. 10,12 (2015): 1851-3. doi: https://doi.org/10.2217/nnm.15.74
Bosetti R. Cost-effectiveness of nanomedicine: the path to a future successful and dominant market?. Nanomedicine (Lond). 2015 Jul;10(12):1851-3. doi: 10.2217/nnm.15.74. PMID: 26139120.
Copy Download .nbib Format: NLM
Medicinal Chemists of the 21(st) Century--Who Are We and Where to Go?.

ChemMedChem

Nussbaumer P.
PMID: 25924977
ChemMedChem. 2015 Jul;10(7):1133-9. doi: 10.1002/cmdc.201500133. Epub 2015 Apr 29.

Many recent articles have dealt with the future challenges in medicinal chemistry. Here, I discuss my concerns over the future of medicinal chemists, who have to be skilled and knowledgeable in many different fields, particularly in the context of...

Cite
Nussbaumer P. Medicinal Chemists of the 21(st) Century--Who Are We and Where to Go?. ChemMedChem. 2015;10(7):1133-9doi: 10.1002/cmdc.201500133.
Nussbaumer, P. (2015). Medicinal Chemists of the 21(st) Century--Who Are We and Where to Go?. ChemMedChem, 10(7), 1133-9. https://doi.org/10.1002/cmdc.201500133
Nussbaumer, Peter. "Medicinal Chemists of the 21(st) Century--Who Are We and Where to Go?." ChemMedChem vol. 10,7 (2015): 1133-9. doi: https://doi.org/10.1002/cmdc.201500133
Nussbaumer P. Medicinal Chemists of the 21(st) Century--Who Are We and Where to Go?. ChemMedChem. 2015 Jul;10(7):1133-9. doi: 10.1002/cmdc.201500133. Epub 2015 Apr 29. PMID: 25924977.
Copy Download .nbib Format: NLM
R&D productivity rides again?.

Pharmaceutical statistics

Lendrem D, Senn SJ, Lendrem BC, Isaacs JD.
PMID: 25336017
Pharm Stat. 2015 Jan-Feb;14(1):1-3. doi: 10.1002/pst.1653. Epub 2014 Oct 22.

A recent analysis of R&D productivity suggests that there are grounds for 'cautious optimism' that the industry 'turned the corner' in 2008 and is 'on the comeback trail'. We believe that this analysis is flawed and most probably wrong....

Cite
Lendrem D, Senn SJ, Lendrem BC, et al. R&D productivity rides again?. Pharm Stat. 2014;14(1):1-3doi: 10.1002/pst.1653.
Lendrem, D., Senn, S. J., Lendrem, B. C., & Isaacs, J. D. (2015). R&D productivity rides again?. Pharmaceutical statistics, 14(1), 1-3. https://doi.org/10.1002/pst.1653
Lendrem, Dennis, et al. "R&D productivity rides again?." Pharmaceutical statistics vol. 14,1 (2015): 1-3. doi: https://doi.org/10.1002/pst.1653
Lendrem D, Senn SJ, Lendrem BC, Isaacs JD. R&D productivity rides again?. Pharm Stat. 2015 Jan-Feb;14(1):1-3. doi: 10.1002/pst.1653. Epub 2014 Oct 22. PMID: 25336017.
Copy Download .nbib Format: NLM
Academic-industry partnerships 2012.

Nature biotechnology

Huggett B.
PMID: 23657385
Nat Biotechnol. 2013 May;31(5):383. doi: 10.1038/nbt0513-383.

No abstract available.

Cite
Huggett B. Academic-industry partnerships 2012. Nat Biotechnol. 2013;31(5):383doi: 10.1038/nbt0513-383.
Huggett, B. (2013). Academic-industry partnerships 2012. Nature biotechnology, 31(5), 383. https://doi.org/10.1038/nbt0513-383
Huggett, Brady. "Academic-industry partnerships 2012." Nature biotechnology vol. 31,5 (2013): 383. doi: https://doi.org/10.1038/nbt0513-383
Huggett B. Academic-industry partnerships 2012. Nat Biotechnol. 2013 May;31(5):383. doi: 10.1038/nbt0513-383. PMID: 23657385.
Copy Download .nbib Format: NLM
Can we use social media to support content validity of patient-reported outcome instruments in medical product development?.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Rothman M, Gnanaskathy A, Wicks P, Papadopoulos EJ.
PMID: 25595228
Value Health. 2015 Jan;18(1):1-4. doi: 10.1016/j.jval.2014.10.001.

We report a panel designed to open a dialog between pharmaceutical sponsors, regulatory reviewers, and other stakeholders regarding the use of social media to collect data to support the content validity of patient-reported outcome instruments in the context of...

Cite
Rothman M, Gnanaskathy A, Wicks P, et al. Can we use social media to support content validity of patient-reported outcome instruments in medical product development?. Value Health. 2015;18(1):1-4doi: 10.1016/j.jval.2014.10.001.
Rothman, M., Gnanaskathy, A., Wicks, P., & Papadopoulos, E. J. (2015). Can we use social media to support content validity of patient-reported outcome instruments in medical product development?. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18(1), 1-4. https://doi.org/10.1016/j.jval.2014.10.001
Rothman, Margaret, et al. "Can we use social media to support content validity of patient-reported outcome instruments in medical product development?." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 18,1 (2015): 1-4. doi: https://doi.org/10.1016/j.jval.2014.10.001
Rothman M, Gnanaskathy A, Wicks P, Papadopoulos EJ. Can we use social media to support content validity of patient-reported outcome instruments in medical product development?. Value Health. 2015 Jan;18(1):1-4. doi: 10.1016/j.jval.2014.10.001. PMID: 25595228.
Copy Download .nbib Format: NLM
Ian Tomlinson.

Nature reviews. Drug discovery

Tomlinson I.
PMID: 26893183
Nat Rev Drug Discov. 2016 Mar;15(3):154. doi: 10.1038/nrd.2016.22. Epub 2016 Feb 19.

No abstract available.

Cite
Tomlinson I. Ian Tomlinson. Nat Rev Drug Discov. 2016;15(3):154doi: 10.1038/nrd.2016.22.
Tomlinson, I. (2016). Ian Tomlinson. Nature reviews. Drug discovery, 15(3), 154. https://doi.org/10.1038/nrd.2016.22
Tomlinson, Ian. "Ian Tomlinson." Nature reviews. Drug discovery vol. 15,3 (2016): 154. doi: https://doi.org/10.1038/nrd.2016.22
Tomlinson I. Ian Tomlinson. Nat Rev Drug Discov. 2016 Mar;15(3):154. doi: 10.1038/nrd.2016.22. Epub 2016 Feb 19. PMID: 26893183.
Copy Download .nbib Format: NLM
Embedding sustainable practices into pharmaceutical R&D: what are the challenges?.

Future medicinal chemistry

Sneddon H.
PMID: 25329193
Future Med Chem. 2014;6(12):1373-6. doi: 10.4155/fmc.14.91.

No abstract available.

Cite
Sneddon H. Embedding sustainable practices into pharmaceutical R&D: what are the challenges?. Future Med Chem. 2014;6(12):1373-6doi: 10.4155/fmc.14.91.
Sneddon, H. (2014). Embedding sustainable practices into pharmaceutical R&D: what are the challenges?. Future medicinal chemistry, 6(12), 1373-6. https://doi.org/10.4155/fmc.14.91
Sneddon, Helen. "Embedding sustainable practices into pharmaceutical R&D: what are the challenges?." Future medicinal chemistry vol. 6,12 (2014): 1373-6. doi: https://doi.org/10.4155/fmc.14.91
Sneddon H. Embedding sustainable practices into pharmaceutical R&D: what are the challenges?. Future Med Chem. 2014;6(12):1373-6. doi: 10.4155/fmc.14.91. PMID: 25329193.
Copy Download .nbib Format: NLM
Panning for gold: sourcing pharmaceutical innovation.

Nature reviews. Drug discovery

Cha M, Saxena A, Smietana K, Bansal R.
PMID: 26000724
Nat Rev Drug Discov. 2015 Jun;14(6):376. doi: 10.1038/nrd4647. Epub 2015 May 22.

No abstract available.

Cite
Cha M, Saxena A, Smietana K, et al. Panning for gold: sourcing pharmaceutical innovation. Nat Rev Drug Discov. 2015;14(6):376doi: 10.1038/nrd4647.
Cha, M., Saxena, A., Smietana, K., & Bansal, R. (2015). Panning for gold: sourcing pharmaceutical innovation. Nature reviews. Drug discovery, 14(6), 376. https://doi.org/10.1038/nrd4647
Cha, Myoung, et al. "Panning for gold: sourcing pharmaceutical innovation." Nature reviews. Drug discovery vol. 14,6 (2015): 376. doi: https://doi.org/10.1038/nrd4647
Cha M, Saxena A, Smietana K, Bansal R. Panning for gold: sourcing pharmaceutical innovation. Nat Rev Drug Discov. 2015 Jun;14(6):376. doi: 10.1038/nrd4647. Epub 2015 May 22. PMID: 26000724.
Copy Download .nbib Format: NLM
Realism in drug discovery-could Cassandra be right?.

Nature biotechnology

Horrobin DF.
PMID: 11731767
Nat Biotechnol. 2001 Dec;19(12):1099-100. doi: 10.1038/nbt1201-1099.

No abstract available.

Cite
Horrobin DF. Realism in drug discovery-could Cassandra be right?. Nat Biotechnol. 2001;19(12):1099-100doi: 10.1038/nbt1201-1099.
Horrobin, D. F. (2001). Realism in drug discovery-could Cassandra be right?. Nature biotechnology, 19(12), 1099-100. https://doi.org/10.1038/nbt1201-1099
Horrobin, D F. "Realism in drug discovery-could Cassandra be right?." Nature biotechnology vol. 19,12 (2001): 1099-100. doi: https://doi.org/10.1038/nbt1201-1099
Horrobin DF. Realism in drug discovery-could Cassandra be right?. Nat Biotechnol. 2001 Dec;19(12):1099-100. doi: 10.1038/nbt1201-1099. PMID: 11731767.
Copy Download .nbib Format: NLM
The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing.

Nature biotechnology

Archer R.
PMID: 10471905
Nat Biotechnol. 1999 Sep;17(9):834. doi: 10.1038/12782.

No abstract available.

Cite
Archer R. The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing. Nat Biotechnol. 1999;17(9):834doi: 10.1038/12782.
Archer, R. (1999). The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing. Nature biotechnology, 17(9), 834. https://doi.org/10.1038/12782
Archer, R. "The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing." Nature biotechnology vol. 17,9 (1999): 834. doi: https://doi.org/10.1038/12782
Archer R. The drug discovery factory: An inevitable evolutionary consequence of high-throughput parallel processing. Nat Biotechnol. 1999 Sep;17(9):834. doi: 10.1038/12782. PMID: 10471905.
Copy Download .nbib Format: NLM
ArQule-Pfizer deal breaks mold.

Nature biotechnology

Dorey E.
PMID: 10471914
Nat Biotechnol. 1999 Sep;17(9):843-4. doi: 10.1038/12825.

No abstract available.

Cite
Dorey E. ArQule-Pfizer deal breaks mold. Nat Biotechnol. 1999;17(9):843-4doi: 10.1038/12825.
Dorey, E. (1999). ArQule-Pfizer deal breaks mold. Nature biotechnology, 17(9), 843-4. https://doi.org/10.1038/12825
Dorey, E. "ArQule-Pfizer deal breaks mold." Nature biotechnology vol. 17,9 (1999): 843-4. doi: https://doi.org/10.1038/12825
Dorey E. ArQule-Pfizer deal breaks mold. Nat Biotechnol. 1999 Sep;17(9):843-4. doi: 10.1038/12825. PMID: 10471914.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 130 entries